Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия; 2 Бюджетное учреждение здравоохранения Омской области «Больница скорой медицинской помощи № 2», Омск, Россия ppi100@mail.ru
Список исп. литературыСкрыть список 1. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020; 22 (8): 1342–56. DOI: 10.1002/ ejhf.1858 2. Dick S.A., Epelman S. Chronic Heart Failure and Inflammation: What Do We Really Know. Circ Res. 2016; 119 (1): 159–76 DOI:10.1161/CIRCRESAHA.116.308030 3. Van Heerebeek L, Hamdani N, Falcao-Pires I et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 2012; 126 (7): 830–9. DOI: 10.1161/CIRCULATIONAHA.111.076075 4. Tromp J Khan MA, Klip IT et al. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction. J Am Heart Assoc 2017; 6 (4): e003989. DOI: 10.1161/JAHA.116.003989 5. Packer M. Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment. Eur J Heart Fail 2020; 22 (2): 214–27. DOI:10. 1002/ejhf.1646 6. Van Linthout S. Tschope C. Inflammation – Cause or Consequence of Heart Failure or Both? Curr Heart Fail Rep 2017; 14 (4): 251–65. DOI: 10.1007/s11897-017-0337-9 7. Tromp J, Westenbrink BD, Ouwerkerk W et al. Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. J Am Coll Cardiol 2018; 72 (10): 1081–90. DOI:10.1016/j.jacc.2018.06.050 8. Brunner-La Rocca HP, Sanders-van Wijk S. Natriuretic Peptides in Chronic Heart Failure. Card Fail Rev 2019; 5 (1): 44–9. DOI:10. 15420/cfr.2018.26.1 9. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223): 507–13. DOI:10.1016/S0140-6736(20)30211-7 10. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054–62. DOI:10.1016/ S0140-6736(20)30566-3 11. Tan ZC, Fu LH, Wang DD, Hong K. Cardiac manifestations of patients with COVID-19 pneumonia and related treatment recommendations. Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48 (0): E005. DOI:10.3760/cma.j.issn.cn112148-20200213-00077 12. Klok FA Kruip MJHA, van der Meer NJM et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145–7. DOI:10.1016/j.thromres.2020.04.013 13. Grillet F Behr J, Calame P, Aubry S, Delabrousse E. Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected with Pulmonary CT Angiography. Radiology 2020; 296 (3): E186–E188. DOI:10.1148/radiol.2020201544 14. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31 (4): 256–63. DOI:10.1053/ sarh.2002.28303 15. Zhang Y, Xiao M, Zhang S et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med 2020; 382 (17): e38. DOI:10.1056/NEJMc2007575 16. O'Sullivan JM, Gonagle DM, Ward SE et al. Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematol 2020; 7 (8): e553-e555. DOI:10.1016/S2352-3026(20)30215-5 17. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004; 6 (3): 261–8. DOI:10.1016/j.ejheart.2004.01.004 18. Алиева А.М., Никитин И.Г., Стародубова А.В. и др. Диагностическая и прогностическая значимость натрийуретических пептидов у кардиологических больных. Лечебное дело. 2016; 3: 78–84. URL: https://www.elibrary.ru/item.asp?id=27327547 [Alieva A.M., Nikitin I.G., Starodubova A.V. et al. Diagnostic and prognostic significance of natriuretic peptides in cardiac patients. Therapeutics. 2016; 3: 78–84 (in Russian).] 19. Han H, Xie L, Liu R et al. Analysis of heart injury laboratory parameters in 273 COVID‐19 patients in one hospital in Wuhan China. J Med Virol 2020; 92: (7) 819–23. DOI:10.1002/jmv.25809 20. Obokata M, Reddy YNV, Melenovsky V et al. Myocardial injury and cardiac reserve in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 2018; 72: 29–40. DOI:10.1016/ j.jacc.2018.04.039 21. Januzzi JL Jr, Filippatos G, Nieminen M, Gheorghiade M. Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J 2012; 33 (18): 2265–71. DOI:10.1093/eurheartj/ehs191 22. Pandey A, Golwala H, Sheng S et al. Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program. JAMA Cardiol 2017; 2 (2): 136–45. DOI:10.1001/ jamacardio.2016.4726 23. Brouwers FP, van Gilst WH, Damman K et al. Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community-based cohort. Circ Heart Fail 2014; 7 (5): 723–31. DOI:10.1161/CIRCHEARTFAILURE.114.001185 24. Thawabi M, Hawatmeh A, Studyvin S et al. Cardiac troponin and outcome in decompensated heart failure with preserved ejection fraction. Cardiovasc Diagn Ther 2017; 7 (4): 359–66. DOI:10.21037/ cdt.2017.03.17 25. Suzuki S, Motoki H, Minamisawa M et al. Prognostic significance of high-sensitivity cardiac troponin in patients with heart failure with preserved ejection fraction. Heart Vessels 2019; 34 (10): 1650–56. DOI: 10.1007/s00380-019-01393-2 26. Shi S, Qin M, Shen B et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 2020; 5 (7): 802–10. DOI:10.1001/jamacardio.2020.0950 27. Mishra AK, Sahu KK, Lal A, Sargent J. Patterns of heart injury in COVID-19 and relation to outcome. J Med Virol 2020; 92 (10): 1747. DOI:10.1002/jmv.25847 28. Huang L Liang L, Tian P et al. D-dimer and outcomes in hospitalized heart failure patients across the ejection fraction phenotypes ESC. Heart Fail 2022 Jun 23. DOI:10.1002/ehf2.14049 29. Rostami M Mansouritorghabeh H. D-dimer level in COVID-19 infection: a systematic review. Expert Rev Hematol 2020; 13 (11): 1265–75. DOI:10.1080/17474086.2020.1831383 30. Ragusa R, Basta G, Del Turco S, Caselli C. A possible role for ST2 as prognostic biomarker for COVID-19. Vascul Pharmacol 2021; 138: 106857. DOI:10.1016/j.vph.2021.106857